Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 14/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178368 | 0.86 | CYP2C9 (0.48) | ALDH1A1CYP2C9CYP2C19MAPK1TDP1 | |
| SCHEMBL1424939 | 0.84 | CYP2C9 (0.47) | ALDH1A1HPGDCYP2C9CYP2C19MAPK1 | |
| SCHEMBL3725916 | 0.81 | CYP2C9 (0.43) | ALDH1A1HPGDCYP2C9CYP2C19TDP1 | |
| SCHEMBL31050105 | 0.79 | ALDH1A1 (0.61) | ALDH1A1CYP2C9CYP2C19MAPK1P2RY12 | |
| SCHEMBL337203 | 0.79 | ALDH1A1 (0.61) | ALDH1A1CYP2C9CYP2C19MAPK1P2RY12 | |
| SCHEMBL14831259 | 0.78 | ALDH1A1 (0.51) | ALDH1A1CYP2C9CYP2C19MAPK1P2RY12 | |
| SCHEMBL15351663 | 0.78 | CYP2C9 (0.51) | ALDH1A1CYP2C9CYP2C19MAPK1P2RY12 | |
| SCHEMBL5320922 | 0.77 | CYP2C9 (0.50) | ALDH1A1CYP2C9CYP2C19MAPK1P2RY12 | |
| SCHEMBL336406 | 0.77 | CYP2C9 (0.50) | ALDH1A1CYP2C9CYP2C19MAPK1P2RY12 | |
| SCHEMBL28080919 | 0.75 | CYP2C9 (0.49) | ALDH1A1CYP2C9CYP2C19MAPK1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069335-B1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-8288554-B2 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-01 | — | — | US | disclosed |
| EP-2069335-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008029370-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | CD4, FCGRT, CD47 | ALDH1A1 1077/4885HPGD 750/4885CYP2C9 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.